Zenabis

Zenabis

Zenabis aims to be one of the largest licensed producers of medical and recreational cannabis in the world.

Company Overview

When Zenabis and Bevo Agro merged to form Zenabis Global Inc. (TSX: ZENA), the deal brought together two families rooted in Canadian agriculture for more than 30 years. This story began as a result of an inter-generational relationship beginning with two immigrant fathers who collaborated in commercial agriculture and continues with their sons partnering to create this new entity. Each partner brings a certain specialty: High quality cannabis for worldwide distribution from Zenabis, and greenhouse growing expertise from Bevo that allows us to efficiently cultivate cannabis at a low cost. They are a diverse, passionate team of doctors, scientists, researchers, growers, educators, and advocates who came together with the goal of increasing access to safe, high quality cannabis for medical patients and recreational consumers. Their four facilities are located coast-to-coast across Canada in Delta and Langley, British Columbia; Atholville, New Brunswick; and Stellarton, Nova Scotia. Zenabis currently owns 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production. The Zenabis brand name is used among the medical market, while Namaste and Blazery service the recreational market.

About Zenabis

HQ Location
Vancouver, BC
Founded
2013
Ownership
public

Related Franchise Content

Franchise

School of Rock Taps Latin America Master Franchisor for United Kingdom Expansion

The music educator is taking a new step in its international expansion with a master franchise agreement in the UK — and a familiar face is leading the venture.

Franchise

Know The Franchise Ownership Costs Before You Leap

From initial investments to royalty fees to legal costs, take stock of these numbers before it's too late.

Franchise

What Franchising Can Teach The NFL About The Impact of Private Equity

The NFL is smart to take a thoughtful approach before approving institutional capital's investment in teams.